Jatinder K Lamba

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Genetic factors influencing cytarabine therapy
    Jatinder K Lamba
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA
    Pharmacogenomics 10:1657-74. 2009
  2. pmc Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes
    Jatinder K Lamba
    Department of Experimental and Clinical Pharmacology, University of Minnesota, MN, USA
    Pharmacogenomics 12:327-39. 2011
  3. doi Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors
    Amit K Mitra
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
    Pharmacogenomics 13:1009-21. 2012
  4. pmc Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia
    Amit K Mitra
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Pharmacol Exp Ther 339:9-23. 2011

Research Grants

  1. Pharmacogenetics of Ara-C Metabolic Pathway
    Jatinder Lamba; Fiscal Year: 2009
  2. Pharmacogenetics of Ara-C Metabolic Pathway
    Jatinder K Lamba; Fiscal Year: 2010
  3. Pharmacogenetics of Ara-C Metabolic Pathway
    Jatinder Lamba; Fiscal Year: 2009

Collaborators

Detail Information

Publications4

  1. pmc Genetic factors influencing cytarabine therapy
    Jatinder K Lamba
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA
    Pharmacogenomics 10:1657-74. 2009
    ..The pharmacogenetic studies on ara-C would also be equally applicable to other nucleoside analogs, such as gemcitabine, decitabine, clofarabine and so on, which are metabolized by the same pathway...
  2. pmc Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes
    Jatinder K Lamba
    Department of Experimental and Clinical Pharmacology, University of Minnesota, MN, USA
    Pharmacogenomics 12:327-39. 2011
    ..To identify gene-expression signatures predicting cytarabine response by an integrative analysis of multiple clinical and pharmacological end points in acute myeloid leukemia (AML) patients...
  3. doi Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors
    Amit K Mitra
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
    Pharmacogenomics 13:1009-21. 2012
    ..The aim of this study was to evaluate the association of gemcitabine pathway SNPs with detailed pharmacokinetic measures obtained from solid tumor patients receiving gemcitabine-based therapy...
  4. pmc Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia
    Amit K Mitra
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Pharmacol Exp Ther 339:9-23. 2011
    ..These results suggest that genetic variations in NT5C2 influence its expression and, potentially, cellular responses to nucleoside analogs...

Research Grants3

  1. Pharmacogenetics of Ara-C Metabolic Pathway
    Jatinder Lamba; Fiscal Year: 2009
    ..The proposed research seeks to explain this variability by studying the inherited genetic variation in key genes involved in ara-C metabolism and may, in future, help to optimize ara-C dosing based on patient genetics. ..
  2. Pharmacogenetics of Ara-C Metabolic Pathway
    Jatinder K Lamba; Fiscal Year: 2010
    ..The proposed research seeks to explain this variability by studying the inherited genetic variation in key genes involved in ara-C metabolism and may, in future, help to optimize ara-C dosing based on patient genetics. ..
  3. Pharmacogenetics of Ara-C Metabolic Pathway
    Jatinder Lamba; Fiscal Year: 2009
    ..The proposed research seeks to explain this variability by studying the inherited genetic variation in key genes involved in ara-C metabolism and may, in future, help to optimize ara-C dosing based on patient genetics. ..